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Abstract 
The  β-globin  gene  mutation  in  sickle  cell
anemia results in anemia and repeated bouts
of vascular occlusion. The cumulative effect of
these vasocclusive events is progressive dam-
age  to  many  organs  including  the  kidneys,
lungs, and brain. The transfusion of red blood
cells (RBC) can ameliorate many of these com-
plications,  but  can  be  associated  with  both
acute  and  chronic  complications,  including
iron  overload.  The  objective  of  the  Best
Practices in Transfusion Medicine for Patients
with  Sickle  Cell  Disease  (SCD)  Conference
was to review the available published evidence
and clinical experience surrounding the use of
RBC transfusions for sickle cell disease by a
panel of experts. The expert panel developed
explicit clinical guidelines for the use of RBC in
SCD patients. The panel also made recommen-
dations for further research. A set of guidelines
were produced for dissemination to pertinent
stakeholders.    If  implemented,  these  clinical
pathways have the potential to optimize the use
of red blood cell transfusions in SCD.
Introduction
Sickle cell anemia was the first recognized
“molecular disease”. A single DNA base muta-
tion, leading to a single amino acid substitution
(Glu to Val), results in hemoglobin S (HbS), the
major hemoglobin defect, and a myriad of clini-
cal  manifestations.
1 Acute  clinical  manifesta-
tions  include  painful  crisis,  acute  chest  syn-
drome, stroke, and priapism.  Irreversible major
organ damage occurs to the brain, heart, lungs,
kidneys, eyes, and femoral heads. Although ane-
mia accounts for some of the morbidity of sick-
le  cell  disease,  vascular  occlusion  underlies
most of the acute and chronic complications.
1
The SCD phenotype is predominantly expressed
in those with homozygous S (HbSS), or com-
pound heterozygotes of HbS and HbC (HbSC) or




There is no doubt that both acute and chron-
ic  RBC  transfusions,  both  in  the  acute  and
chronic  setting,  can  ameliorate  many  of  the
complications  of  sickle  cell  disease.
2 Some
transfusion  practices,  such  as  perioperative
transfusion,
3 transfusion  during  pregnancy,
4
and  chronic  transfusion  to  prevent  stroke  in
children found to be high-risk from transcranial
doppler (TCD) screening and/or because of pre-
vious  stroke,
5-7 are  based  on  prospective  ran-
domized studies. Other practices, such as trans-
fusion for prolonged painful episodes, exchange
transfusion for acute chest syndrome, and RBC
transfusion for those with pulmonary hyperten-
sion, are based on less firm evidence.
2 Barriers
to chronic transfusion therapy include patient
and  family  reluctance,  inconvenience,  intra-
venous  access  issues,  alloimmunization,  red
cell  availability,  infectious  disease  complica-
tions, immune modulation, and iron overload.
8
Based  on  surveys  from  the  Sickle  Cell  Adult
Provider  Network  (SCAPN),  whereas  transfu-
sion practice for patients with pregnancies is
fairly standard, it varies considerably in adults
with ischemic stroke (K. Hassell, unpublished
communication). 
It was recognized that many practices and
recommendations  regarding  transfusion  of
RBC for patients with SCD were not evidenced
based.  Nonetheless,  it  was  felt  important  to
highlight  those  that  did  have  a  basis  in
prospective, randomized trials, and to catalog
practices that were in common use but not evi-
denced based. At a minimum, such a catalog
could serve as a basis for critically examining
current practices and setting research priori-
ties for future studies. The overall purpose of
the  conference  was  to  provide  succinct  best
practices guidelines for transfusion that had
the potential to improve care.
9
Materials and Methods
This conference was conceived to be part of
a series of five best practices guidelines focus-
ing  on  the  care  of  adult  patients  with  SCD.
This conference was not a “consensus” confer-
ence, nor was it an exhaustive, meta-analyses
or  Cochrane-type  review  of  the  literature.
Rather, it was a focused literature review with
key citations as determined by experts in the
field. For a more comprehensive overview, the
reader is directed to several excellent reviews
on this topic.
2,10-12 Several months prior to the
meeting,  the  conference  coordinator  (TW)
asked each invited expert (Table 1) to forward
succinct recommendations for each assigned
topic and provide key citations. These served as
the basis for the agenda.  
The conference took place September, 2007
immediately preceding the annual Sickle Cell
Clinical Research Meetings and was open to
the public. Each expert was asked to present
her  or  his  recommendations  and  assign  a
strength based on a simplified scoring system
of  Strong,  Moderate,  or  Uncertain  (Table  2)
that  paralleled  ones  used  in  other  guideline
recommendations.
13 At the end of each presen-
tation, comment was invited from the audience
and other panel members.  The final recom-
mendations  were  developed  by  consensus  at
the end of the conference with audience input.
Panel members adhered to several princi-
ples while developing their recommendations.
First, in keeping with the theme, best prac-
tices, as opposed to standard or practical ones,
were to be recommended. The bar was to be set
high to promote what was felt to be optimal
medical care. Second, recommendations were
to be evidence-based if possible, but could also
be based on expert opinion. This was in recog-
nition that very little available data was truly
evidenced-based. In the absence of data specif-
ic to adults, discussants were asked to extrap-
olate from data in children. Finally, panel mem-
bers were asked to be as prescriptive as possi-
ble, without being dogmatic. 
Results
A set of guidelines were produced for dis-
semination to pertinent stakeholders.
Recommendation #1: indications
for acute red blood cell transfusions
Transfusion is indicated for the therapy of
the acute clinical situations detailed in Table
3. This recommendation was strong for acute
chest  syndrome  (ACS)  with  hypoxemia  or
worsening  respiratory  distress,
14,16 ischemic
stroke without or without post-infarct bleed-
ing,
8,17 splenic and hepatic sequestration with
worsening anemia, aplastic crisis with wors-
ening anemia, symptomatic acute blood loss,
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and multiorgan failure.
18 It was acknowledged
that there is neither a universal definition of
acute chest syndrome, nor a system for grading
the severity of ACS.
14-16 Nonetheless, all panel
members  agreed  that  hypoxemia  requiring
supplemental oxygen and/or worsening tachyp-
nea were indications. It was also recognized
that the term “significant decrease from base-
line” in regards to splenic and hepatic seques-
tration is subjective. This determination is best
made by clinicians under specific clinical cir-
cumstances. For isolated intracerebral hemor-
rhage,  transfusions  are  of  uncertain  benefit
and,  anecdotally,  have  exacerbated  central
nervous system (CNS) bleeding. Nonetheless,
in cases where there was an infarctive compo-
nent to the bleed, some panel members felt that
transfusion might be useful. Panel members
were in more agreement about transfusion for
transient ischemic attacks (TIA), but there are
some data suggesting that transfusions are not
effective  at  prevention:
19 however,  in  the
absence of clinical trials, this recommendation
was graded as only moderate. Silent cerebral
infarcts (SCI) were not addressed at this con-
ference, but there are some data to suggest that
transfusion may lower the incidence of SCI as
defined by MRI.
20 However, as these data were
generated in children who would be considered
candidates for transfusion therapy regardless
(because of high risk TCD findings), a separate
recommendation  may  not  be  necessary.  The
indications  for  red  blood  cell  transfusion  for
severe infections and persistent priapism are
based  on  less  convincing  anecdotes  and  are
thus uncertain.
21 The association of sickle cell
disease, priapism, exchange transfusion, and
neurological  events  (ASPEN  syndrome)  was
also of concern regarding transfusion therapy
for priapism.
21,22 Because the ASPEN syndrome
is  based  largely  on  case  reports,  there  was
insufficient  evidence  to  consider  priapism  a
contraindication to transfusion. A recent report
suggested that exchange transfusion was safe
and  efficacious  if  the  resulting  hemoglobin
level was <11 g/dL,
22 suggests that ASPEN syn-
drome results from increased whole blood vis-
cosity.
Recommendation #2: red cell 
transfusion is not indicated for 
the therapy of uncomplicated acute
painful episodes regardless of
duration 
The panel discussed that RBC transfusion
during otherwise typical painful episodes was
common in both community and academic set-
tings but there was little to no evidence to sup-
port this practice.
23 The term uncomplicated in
this context means without the indications for
acute  transfusion  stated  in  recommendation
#1. The panel felt that this practice should be
discouraged,  therefore  warranted  a  separate
recommendation to emphasize the point.  
Recommendation #3: acute red cell
transfusion is not indicated for a
decrease in hemoglobin from 
baseline not associated with 
symptoms of anemia
In a certain sense, this recommendation is
in  concert  with  #2.  Patients  with  SCD  have
variable  severity  of  chronic  anemia.  Physio-
logical  compensation  includes  high  cardiac
output  and  increased  plasma  volume.  The
practice of routine transfusion for an arbitrary
level of hemoglobin should be discouraged in
SCD  patients  and  all  patients.  The  panel
emphasized that patients with chronic anemia
may be more sensitive to volume challenge and
prone  to  develop  symptomatic  volume  over-
load.  Whether a patient tolerates a specific
level of hemoglobin depends on the clinical cir-
cumstances (e.g., infection, rapidity of decline,
co-morbid conditions) and the determination
of  whether  the  anemia  is  “symptomatic”  is
somewhat subjective. This recommendation is
dependent on sound clinical judgment.  
Recommendation #4: prophylactic
red cell transfusions
Red  cell  transfusions  can  be  used  in  the
prevention  of  sickle  cell  complications.  The
panel felt that these should be strongly recom-
mended for high risk surgical procedures,
3,24,25
secondary prevention of stroke, and primary
prevention of stroke in those children identi-
fied  as  high  risk  by  TCD  examination.
5,7 In
patients  requiring  general  anesthesia  with
evidence  of  cardiac,  pulmonary,  renal,  or
hepatic  dysfunction,  many  panelists  and
attendees also felt red cell transfusions were
indicated. The panel discussed general anes-
thesia is likely not the issue, but rather proce-
dure times of 45-60 minutes or longer place
patients at higher risk for complications, pre-
dominantly  pulmonary.  There  was  disagree-
ment as to what constituted a high risk surgi-
cal procedure. There was agreement that open
thoracic and vascular procedures were high
risk, but hip and knee replacement might be
considered moderate risk (similar to cholecys-
tectomy). Abdominal procedures may also be
associated with increased risk, particularly in
patients with HbSC disease.
26 Anecdotal expe-
rience suggests that prophylactic transfusions
can reduce the frequency of painful episodes
in patients refractory to hydroxyurea, but only
as part of a comprehensive pain program.
Recommendation #5: chronic
transfusion may be useful in 
stabilizing or reversing certain 
end-organ dysfunction
These include pulmonary hypertension, con-
gestive  heart  failure,  and  renal  dysfunction.
However,  this  recommendation  is  almost
entirely based on personal experience and/or
anecdotal reports. Many participants observed
Table 1. Speakers and topics.
Marilyn J. Telen, M.D., Wellcome Professor of Medicine and Chief of Hematology, Duke University
Medical Center
Indications for acute and chronic red cell transfusions
Naomi L.C. Luban, M.D., Professor of Pediatrics and Pathology, Chief of Laboratory Medicine and
Pathology, Children’s National Medical Center
Selection of the appropriate red cell product
Paul V. Holland, M.D., Clinical Professor of Medicine and Pathology, UC Davis School of Medicine
Infectious and immunologic complications of transfusion in patients with SCD
Paul Swerdlow, M.D., Professor of Medicine, Wayne State University School of Medicine
Exchange versus simple transfusion, Hb and HbS target
Elliot P. Vichinsky, M.D., Director, Hematology and Oncology, Children’s Hospital Oakland Research
Institute
Perioperative transfusions
Gary Brittenham, M.D., Professor of Medicine and Pediatrics, Columbia University College of Physicians
and Surgeons
Assessment and Management of iron overload in patients with SCD
Table 2. Definition of grading.
Strong
At least one, prospective randomized study in adults or a randomized study where a non-transfusion 
arm was considered unethical by the panel
Moderate
Prospective, randomized data from children
Prospective, non-randomized or observational studies in adults or children
Definitive study is thought not feasible by the panel
Uncertain
Retrospective studies or case reports in adults or children[page 108] [Hematology Reviews 2009; 1:e22]
that  aggressive  local  therapy  was  the  most
effective treatment for non-healing leg ulcers.
As the sickle cell population ages and develops
more chronic end-organ dysfunction, this will
be an important area for research.
Recommendation #6: type of red
cell product
The red blood cell products used for transfu-
sion in patients with SCD should all be leuko-
cyte-reduced,  sickle  hemoglobin  negative,
matched for at least the red cell antigens Cc,
Ee,  and  K  and  any  antigens  for  which  the
patients has developed alloantibodies (past or
present).  Alloimmunization  to  red  cell  anti-
gens is a common occurrence in transfused
SCD patients.
27,28 Limited phenotype-matching
has been shown to decrease significantly the
rate of alloimmunization amongst non-alloim-
munized sickle cell patients.
29 Recent studies
showed  that  limited  phenotype-matching  is
practiced by a minority of transfusion medi-
cine  services  surveyed  in  North  America.
30
Discussion centered on the fact that not all cel-
lular blood products in the US are pre-storage
leukocyte reduced. While this is the standard
in  the  European  Union  and  the  United
Kingdom, only about 70% of blood banks in the
United  States  routinely  stock  pre-storage
leukocyte reduced products. Not all transfusion
medicine  services  verify  that  blood  being
transfused to a SCD patient is sickle hemoglo-
bin negative.  In areas where there is a large
African American blood donor population, this
issue becomes more relevant.
Recommendation #7: target
hemogoblin level
When transfusing red blood cells for acute
indications, the target hemoglobin and hemat-
ocrit level should not exceed 10 g/dL and 30%,
respectively.  The panel and audience believed
that there were sufficient rheological data and
rationale  to  avoid  higher  levels  to  prevent
increases in whole blood viscosity.
31-33 In addi-
tion, there is some clinical evidence suggest-
ing  that  acute  clinical  deterioration  occurs
when  whole  blood  viscosity  is  suddenly
increased  (ASPEN  Syndrome  noted  above).
The panel acknowledged that much of the data
were generated in vitro; nonetheless, this rec-
ommendation was strong.  
Recommendation #8: target HbA
level
For acute exchange transfusions, a level of
HbA% >70% should be targeted. It was acknowl-
edged that this has never been rigorously stud-
ied. Establishing a target in terms of the per-
centage of HbA rather than HbS was more sen-
sible for compound heterozygous patients. For
example, it is simpler to target raising the HbA




Acute complications requiring acute red cell transfusion
Acute Chest Syndrome with hypoxemia, or increasing respiratory distress (Strong)
Without hypoxemia or increasing respiratory distress (Moderate)
Acute stroke (ischemic with or without bleed) (Strong)
Isolated intracranial hemorrhage (Uncertain with caveat)
TIA (Moderate)
Retinal Artery Occlusion (Moderate)
Acute splenic sequestration with a significant drop from baseline Hb (Strong)
Acute hepatic sequestration (Strong)
Aplastic crisis (Strong)
Significant, symptomatic acute blood loss (Strong)
Persistent priapism (Uncertain)
Multiorgan failure syndrome (Strong)
Acute life-threatening infection (Uncertain)
#2
Acute red cell transfusion is not indicated for the therapy of uncomplicated painful episodes regard-
less of duration (Strong)
#3
Acute red cell transfusion is not indicated for a decrease in hemoglobin from baseline not associated 
with symptoms of anemia (Strong)
#4
Prophylactic red cell transfusions are indicated for
High risk surgical procedures (Strong)
Surgical procedure requiring anesthesia in a patient with evidence of significant end-organ dam-
age (Moderate)
Cardiac, pulmonary, renal, hepatic insufficiency (Uncertain)
Secondary prevention of stroke (Strong)
For patients who had strokes as children and are now adults (Moderate)
Primary prevention of stroke for patients who were identified as children as being high risk (Strong)
Refractory (to hydroxyurea), frequent painful episodes same evidence as a component 
of a comprehensive pain protocol (Moderate)
Exacerbation of SCD during pregnancy (Moderate)
Consider if acute Hb < 6.0 g/dL (Moderate)
#5
Chronic transfusion may be useful in stabilizing or reversing
Progressive congestive heart failure (Moderate) 
Progressive chronic renal insufficiency (Uncertain)
Progressive pulmonary hypertension (Uncertain)
Elevated tricuspid regurgitant jet (Uncertain)
Non-healing leg ulcer (Uncertain)
#6
The red blood cells given to patients with sickle cell disease should be
Leukocyte-reduced (pre-storage strongly preferred) (Strong)
Antigen-matched for Cc, Ee, K and any antigens for which there is a clinically significant alloanti-
body currently present or in the past (Strong)
Hemoglobin S negative (Strong)
#7
For acute sickle cell complications, the dose of red cells should be calculated to result in a Hb 
≤10 g/dL or ≤Hct 30% (Strong)
#8
The goal of exchange transfusion for acute indications is to achieve a HbA > 70% on post-transfusion 
hemoglobin fractionation (Strong)
The preferred method is erythrocytapheresis with residual HbS < 30% (Strong)
#9
Exchange transfusion is preferred over simple transfusion in adults for
Acute stroke (Strong)
Severe acute chest syndrome (Strong)
Multi-organ failure (Strong)
Preoperative transfusion with baseline Hb > 10 g/dL (Moderate)
Transfusion of volume sensitive patients (Moderate)
Hyperosmolar contrast agents (Uncertain)
Refractory priapism (Uncertain)
#10
Every patient with sickle cell disease should be vaccinated for hepatitis A/B (Strong)
continued on next page[Hematology Reviews 2009; 1:e22] [page 109]
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HbS of 15% and HbC of 15%.
11 The preferred
method for exchange is automated erythrocyta-
pheresis.  In the absence of an apheresis serv-
ice or because of patient preference, manual
exchange is a suitable alternative.
17
Recommendation #9: simple vs
exchange transfusion
There  are  few  data  comparing  simple  to
exchange transfusion. Exchange was preferred
strongly over simple transfusion for the treat-
ment of severe acute chest syndrome, stroke,
and multi-organ failure. A multi-center, ran-
domized study showed exchange transfusion
to be non-superior to simple transfusion in the
perioperative  setting.
24 However,  the  panel
endorsed the use of exchange as preferable in
advance of high risk operations. There was no
clarity as to which modality was preferable in
the setting of acute priapism and use of hyper-
osmolar contrast agents, with the latter just to
be avoided with the availability of iso-osomot-
ic contrast agents.
Recommendation #10: vaccination
Every sickle cell patient should be vaccinat-
ed for hepatitis A and B as early as possible to
prevent  post-transfusion  infection.  This  was
non-controversial and strong.  
Recommendation #11: iron assess-
ment
There was consensus that chronically trans-
fused  sickle  cell  disease  patients  should  be
regularly  assessed  for  iron  overload  and
offered chelation therapy to decrease the risk
of iron related toxicity. There was considerable
discussion regarding the number of lifetime
transfusions  that  should  trigger  an  assess-
ment of iron stores, and the optimal methods
and  extent  of  this  assessment.
34 The  panel
noted that some published recommendations
are an extrapolation from the experience with
β-thalassemia patients whose iron burden is
significantly higher based on pathophysiology
of their disease.
35-37 Despite limited evidence,
the consensus of the panel is that the hepatic
storage  iron  concentration  should  be  main-
tained below a threshold of 15 mg Fe/g liver,
dry weight, to avoid progression to liver fibro-
sis and a target range of 3 to 7 mg Fe/g liver,
dry weight, is recommended as prudent. Liver
biopsy with its inherent risks is still the stan-
dard, but MRI T2* can also be used and its
availability is only a function of proper calibra-
tion. Centers taking care of chronic transfu-
sion patients should develop the ability to offer
this mode of iron assessment.  
Recommendation #12
Every patient with sickle cell disease should
have  a  portable  comprehensive  transfusion
record, including phenotype, type and number
of  transfusions,  alloantibody  status  and
adverse  events.    Strongly  advocated  by  the
patients  present,  this  again  would  ensure




There  should  be  a  system  for  sharing
patient  information  on  RBC  phenotype,  and
alloantibody and autoantibody status amongst
regional  blood  providers.  While  allowing  for
privacy concerns, this was felt to be necessary
to avoid further alloimmunization, hemolytic
transfusion  reactions  due  to  anamnestic
alloantibody  responses  (which  may  simulate
acute  aplasia  and  crisis
38),  and  help  ensure
availability of appropriately selected RBC prod-
ucts.  This  recommendation  was  stressed  by
patients and family members in attendance.
Conclusions
If  implemented,  these  clinical  pathways
have the potential to optimize the use of red
blood cell transfusions in SCD.
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